Wayne Rothbaum | $1B+

Billionaire
Written By UHNWI data

Get in touch with Wayne Rothbaum | Wayne Rothbaum, founder of Quogue Capital, built a private investment firm focused on opportunistic public equities, private investments, and long-term capital allocation across multiple asset classes. After an early career in finance and investing, Rothbaum developed Quogue into a discreet family office-style platform known for concentrated positions and patient ownership. Operating with a low public profile, he has deployed capital across technology, media, and consumer businesses while maintaining a disciplined, research-driven approach to investing.

Get in touch with Wayne Rothbaum
Wayne Rothbaum, founder of Quogue Capital, built a private investment firm focused on opportunistic public equities, private investments, and long-term capital allocation across multiple asset classes. After an early career in finance and investing, Rothbaum developed Quogue into a discreet family office-style platform known for concentrated positions and patient ownership. Operating with a low public profile, he has deployed capital across technology, media, and consumer businesses while maintaining a disciplined, research-driven approach to investing. Wayne Rothbaum, who founded investment firm Quogue Capital in 2001, became a wildly successful biotech investor, deploying only his own funds. In 2012, Rothbaum cofounded and became the largest investor in cancer drug developer Acerta Pharma, whose drug Calquence was approved to treat forms of lymphoma and leukemia. In 2016, AstraZeneca paid $4 billion for 55% of Acerta Pharma and agreed to acquire the remainder of Acerta for nearly $2.5 billion paid between 2022 and 2024. Rothbaum is executive chair of two cancer drug firms: Kartos Therapeutics, which he cofounded in 2016, and Telios Pharma, cofounded in 2019. Rothbaum also led a restructuring of listed biotech firm Iovance Biotherapeutics, where he is a board member and the largest shareholder, with a stake of more than 10%.

Disclaimer: This profile is based on publicly available information. No endorsement or affiliation is implied.

Join UHNWI direct Affiliate Program

Earn Passive Income by Sharing Verified Contact Information of Billionaires, Centi-Millionaires, and Multi-Millionaires on the UHNWI Direct Platform

Maximize your earnings potential by sharing direct and validated contact information of the ultra-wealthy, including billionaires, centi-millionaires, and multi-millionaires. Join the UHNWI Direct platform and tap into a lucrative passive income stream by providing valuable data to those seeking high-net-worth connections. Start earning today with UHNWI Direct.

Apply to Join Affiliate Program

You may also be interested in reviewing other UHNWIs profiles.

To find the person you want to contact, start typing their name or other relevant tags in the search bar.

Please note: Our database contains over 10,000 direct contacts of UHNWIs, and it is highly likely that the individual you are seeking is already included. However, creating individual profiles for each contact is a meticulous and time-intensive process, So, if you are unable to find the profile of the individual you are looking for, please click here.

Filter by Net Worth: All | Billionaires | Centi-Millionaires | Multi-Millionaires

Filter by Location: All | USA | Canada | Europe | UK | Russia & CIS | Asia | MEIA | Australia | Latin America

Filter by Age: 1920-1930 | 1930-1940 | 1940-1950 | 1950-1960 | 1960-1970 | 1970-1980 | 1980-1990 | 1990-2000

Filter by: Men | Women

Related People

UHNWI direct
Wayne Rothbaum | $1B+
Wayne Rothbaum | $1B+

Wayne Rothbaum, founder of Quogue Capital, built a private investment firm focused on opportunistic public equities, private investments, and long-term capital allocation across multiple asset classes. After an early career in finance and investing, Rothbaum developed Quogue into a discreet family office-style platform known for concentrated positions and patient ownership. Operating with a low public profile, he has deployed capital across technology, media, and consumer businesses while maintaining a disciplined, research-driven approach to investing.

Read More →
Timothy Springer | $1B+
Timothy Springer | $1B+

Timothy Springer is the Latham Family Professor at Harvard Medical School and a billionaire biotech pioneer known for his foundational work in immunology. He discovered the first integrins and adhesion molecules (ICAMs), discoveries that led to blockbusters like Entyvio and Raptiva. A founding investor in Moderna, he famously turned a $5 million stake into billions, cementing his status as one of the world's wealthiest academics. In 2026, he continues to lead the Institute for Protein Innovation (IPI), a legacy nonprofit he endowed with $210 million to advance open-source protein research. Recently, he was elected a Fellow of the National Academy of Inventors and made headlines for his massive $61 million investment in Tectonic Therapeutic. Beyond science, he is an avid collector of gongshi (Chinese scholar's rocks).

Read More →
Robert Duggan | $10B+
Robert Duggan | $10B+

Robert Duggan, biotech entrepreneur and investor, built his fortune by identifying overlooked medical assets and scaling them into blockbuster businesses. He is best known for leading Pharmacyclics as CEO and majority owner, turning the company into a major oncology success through the development of Imbruvica, before selling it to AbbVie in a multibillion-dollar deal. Known for bold conviction, aggressive capital deployment, and a willingness to bet heavily on scientific outcomes, Duggan has become one of the most successful dealmakers in modern biotechnology.

Read More →
Randal Kirk | $1B+
Randal Kirk | $1B+

Randal J. Kirk, biotech entrepreneur and investor, built his fortune by creating and scaling life-sciences companies focused on drug development, specialty pharmaceuticals, and healthcare innovation. Best known as the founder of Intrexon and as the driving force behind multiple public biotech ventures, Kirk has pursued an aggressive strategy of acquiring scientific platforms, recruiting top research talent, and commercializing high-value therapies. His long-term influence spans pharmaceuticals, genetics, and medical technology, reflecting a rare ability to combine capital markets skill with scientific ambition.

Read More →
Pablo Legorreta | $1B+
Pablo Legorreta | $1B+

Pablo Legorreta, founder and CEO of Royalty Pharma, built a category-defining firm by pioneering royalty-based investing in biopharmaceutical innovation. After founding the company in 1996, Legorreta created a model that provides non-dilutive capital to drug developers in exchange for royalty streams on approved medicines, helping finance breakthroughs while managing risk through diversified cash flows. Under his leadership, Royalty Pharma scaled into a multibillion-dollar, publicly traded platform that partners with leading biotech companies and academic institutions worldwide, reshaping how life-science innovation is funded.

Read More →
Noubar Afeyan | $1B+
Noubar Afeyan | $1B+

Noubar Afeyan, founder and CEO of Flagship Pioneering, is a leading biotech entrepreneur and venture creator known for inventing companies at the intersection of science and breakthrough innovation. Through Flagship, he has co-founded and incubated dozens of life-sciences companies, most notably Moderna, helping pioneer the mRNA platform that reshaped vaccine development and global public health. Trained as a chemical engineer, Afeyan combines deep scientific rigor with venture discipline, backing long-horizon technologies across biology, health, and sustainability. His work has made Flagship a cornerstone of modern biotech company creation.

Read More →
Julian Baker | $1B+
Julian Baker | $1B+

Julian Baker, cofounder of Baker Bros. Advisors, is one of the most successful investors in the biotechnology industry, building a multibillion-dollar hedge fund focused on high-conviction positions in drug development and life sciences. Together with his brother Felix, he has backed breakthrough therapeutics and major biotech companies including Seagen, Incyte, and Alexion, often taking large, long-term positions and working closely with management teams. Known for rigorous scientific analysis, patience, and a deep understanding of clinical risk, Baker has become a central figure in biotech capital markets, influencing the trajectory of drug innovation while maintaining one of the top track records in the sector.

Read More →
Felix Baker | $1B+
Felix Baker | $1B+

Felix Baker is a highly influential biotech-focused investor and co-founder of Baker Brothers Advisors, a leading hedge fund specializing in healthcare and biotechnology investing. Through his firm, established in 2000, Felix manages over $20 billion in assets and helped generate an estimated $8 billion gain from early investments in Seagen. A PhD immunologist and Stanford alumnus, he also serves on boards of key biotech companies and contributes to Stanford’s biosciences initiatives.

Read More →

Support our Research

UHNWI data is an independent wealth intelligence initiative led by a team of data researchers dedicated to building the world’s most comprehensive archive of individuals with a net worth exceeding $100 million. We believe in open access to structured knowledge — freely available, meticulously curated, and ethically maintained. This work is complex, time-intensive, and demands significant resources. If you find value in what we do, we invite you to support our mission with a donation. Your contribution helps preserve the independence, depth, and lasting impact of this unique research project.

3% Cover the Fee

Marketing Tools

Essential marketing tools to effectively engage wealthy individuals, tailored to meet any personal, marketing, or sales objectives.

Use tags below for more precise targeting.

UHNWI data https://www.uhnwidata.com/
Previous

Wesley Edens | $1B+
Next

Wayne Hughes, Jr. | $1B+